Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that Dr. Stuart Titus, the Company’s Chief Executive Officer, was featured in several national and international news publications about his speaking engagement at the U.S. Food and Drug Administration (FDA) Hearing on cannabis and cannabidiol (CBD) on Friday, May 31, 2019.
The economic and wellness potential for CBD is nearly impossible to ignore. Just last year, Medical Marijuana, Inc. saw a year-over-year revenue increase of more than 125% over 2017. Also, the Brightfield Group stated in its 2018 Annual Report that the CBD market is expected to grow by nearly 40 times within the next four years, outpacing the rest of the cannabis market, including Tetrahydrocannabinol (THC) marijuana products, to reach $22 billion by 2022. The FDA’s hearing follows on the heels of last year’s Agriculture Improvement Act of 2018 (often referred to as the 2018 Farm Bill), which legalized hemp and hemp-derived CBD production across the country.
“Speaking publicly at this hearing was a historic step for our Company,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We feel very fortunate that our voice in the industry was heard and that we were able to educate the FDA on how CBD supports our Endogenous Cannabinoid System (ECS).”
Titus’ testimony encouraged the FDA to recognize that there is significant published evidence that botanical hemp-derived CBD supplements can support health and wellness by targeting the body’s ECS. He also highlighted that the National Institute of Health (NIH) has recognized CBD’s benefits within Patent #6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants” and by listing CBD in the NIH Dietary Supplement Database.
News publications Titus was featured in include:
To learn more about Medical Marijuana, Inc., please visit www.medicalmarijuanainc.com.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
SOURCE Medical Marijuana, Inc.